Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.

• Tác giả: Nick Andrews, Amanda Bolt Botnen, Magda Bucholc, Simon Cottrell, Hanne-Dorthe Emborg, Safraj Shahul Hameed, Mark Hamilton, Freja Kirsebom, Esther Kissling, Karina Lauenborg Møller, Jamie Lopez-Bernal, Héloïse Lucaccioni, Diogo Fp Marques, Kimberly Marsh, Ross McQueenie, Siobhan Murphy, Mark G O'Doherty, Francisco Pozo, Angela Mc Rose, Ramona Trebbien, Heather Whitaker
• Ngôn ngữ: eng
• Ký hiệu phân loại: 912.01 Philosophy and theory
• Thông tin xuất bản: Sweden : Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin , 2025
• Bộ sưu tập: NCBI
• ID: 238506

Tóm tắt

The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.